Vaccine maker Valneva’s shares slump after UK ends COVID-19 deal

The company’s COVID-19 vaccine candidate VLA 2001 relies on inactivated virus, similar to flu vaccines, and is seen by some as having the potential to win over people who are wary of some current vaccines using new mRNA technology.

Original source: https://health.economictimes.indiatimes.com/news/pharma/86166881?utm_source=RSS&utm_medium=ETRSS

Related Posts